Compare Stocks: LQDA, AXSM, LNTH, and AMRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRX Amneal Pharmaceuticals	$19.57 -2.3%	$18.50	$9.56 ▼ $21.17	$6.25B	1.22	2.26 million shs	5.00 million shs
AXSM Axsome Therapeutics	$156.32 -5.8%	$202.03	$120.12 ▼ $260.19	$8.19B	0.86	759,424 shs	1.33 million shs
LNTH Lantheus	$100.02 -0.1%	$100.47	$50.15 ▼ $111.86	$6.53B	-0.06	1.08 million shs	1.54 million shs
LQDA Liquidia	$26.81 -3.1%	$64.63	$21.94 ▼ $93.61	$2.40B	0.61	2.08 million shs	3.09 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRX Amneal Pharmaceuticals	+0.60%	-1.57%	+17.75%	+20.01%	+100.90%
AXSM Axsome Therapeutics	-1.40%	-6.26%	-24.80%	-29.44%	+36.39%
LNTH Lantheus	-0.04%	-0.08%	-0.14%	-2.21%	+86.98%
LQDA Liquidia	+1.06%	+0.11%	-58.54%	-63.83%	+19.16%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRX Amneal Pharmaceuticals	$19.57 -2.3%	$18.50	$9.56 ▼ $21.17	$6.25B	1.22	2.26 million shs	5.00 million shs
AXSM Axsome Therapeutics	$156.32 -5.8%	$202.03	$120.12 ▼ $260.19	$8.19B	0.86	759,424 shs	1.33 million shs
LNTH Lantheus	$100.02 -0.1%	$100.47	$50.15 ▼ $111.86	$6.53B	-0.06	1.08 million shs	1.54 million shs
LQDA Liquidia	$26.81 -3.1%	$64.63	$21.94 ▼ $93.61	$2.40B	0.61	2.08 million shs	3.09 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRX Amneal Pharmaceuticals	+0.60%	-1.57%	+17.75%	+20.01%	+100.90%
AXSM Axsome Therapeutics	-1.40%	-6.26%	-24.80%	-29.44%	+36.39%
LNTH Lantheus	-0.04%	-0.08%	-0.14%	-2.21%	+86.98%
LQDA Liquidia	+1.06%	+0.11%	-58.54%	-63.83%	+19.16%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMRX Amneal Pharmaceuticals	2.80	Moderate Buy	$21.00	7.31% Upside
AXSM Axsome Therapeutics	2.86	Moderate Buy	$275.74	76.39% Upside
LNTH Lantheus	2.21	Hold	$107.44	7.42% Upside
LQDA Liquidia	2.25	Hold	$83.69	212.17% Upside

Current Analyst Ratings Breakdown

Latest LQDA, AXSM, LNTH, and AMRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/13/2026	LNTH Lantheus	Mizuho Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform ➝ Neutral	$115.00 ➝ $109.00
10/8/2026	LQDA Liquidia	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform
10/8/2026	AMRX Amneal Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Buy (B-) ➝ Buy (B)
10/8/2026	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$297.00 ➝ $295.00
10/6/2026	AMRX Amneal Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
10/2/2026	LQDA Liquidia	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$58.00
10/2/2026	LQDA Liquidia	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight ➝ Equal Weight	$108.00 ➝ $30.00
10/2/2026	LQDA Liquidia	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$130.00 ➝ $58.00
10/1/2026	AMRX Amneal Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/1/2026	LQDA Liquidia	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Strong-Buy ➝ Outperform	$106.00 ➝ $53.00
10/1/2026	LQDA Liquidia	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Neutral

(Data available from 10/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMRX Amneal Pharmaceuticals	$3.02B	2.07	$1.53 per share	12.75	($0.23) per share	-85.09
AXSM Axsome Therapeutics	$638.50M	12.82	N/A	N/A	$1.75 per share	89.33
LNTH Lantheus	$1.54B	4.23	$6.38 per share	15.68	$16.43 per share	6.09
LQDA Liquidia	$158.32M	15.16	N/A	N/A	$0.51 per share	52.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMRX Amneal Pharmaceuticals	$72.06M	$0.49	39.94	18.12	2.34	5.05%	-584.46%	7.78%	N/A
AXSM Axsome Therapeutics	-$183.17M	-$3.75	N/A	41.35	N/A	-24.68%	-265.55%	-28.10%	11/2/2026 (Estimated)
LNTH Lantheus	$233.56M	$4.14	24.16	17.83	N/A	17.69%	28.10%	14.35%	11/5/2026 (Estimated)
LQDA Liquidia	-$68.92M	$1.37	19.57	8.97	N/A	30.74%	149.65%	36.30%	11/2/2026 (Estimated)

Latest LQDA, AXSM, LNTH, and AMRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	LNTH Lantheus	$1.26	N/A	N/A	N/A	$360.82 million	N/A
11/2/2026	Q3 2026	AXSM Axsome Therapeutics	-$0.55	N/A	N/A	N/A	$254.32 million	N/A
11/2/2026	Q3 2026	LQDA Liquidia	$0.8220	N/A	N/A	N/A	$201.54 million	N/A
8/12/2026	Q2 2026	LQDA Liquidia	$0.7580	$0.74	-$0.0180	$0.74	$168.48 million	$171.68 million
8/10/2026	Q2 2026	AXSM Axsome Therapeutics	-$0.8921	-$0.99	-$0.0980	-$0.99	$221.11 million	$218.38 million
8/6/2026	Q2 2026	LNTH Lantheus	$1.30	$1.55	+$0.25	$1.11	$363.23 million	$388.18 million
7/30/2026	Q2 2026	AMRX Amneal Pharmaceuticals	$0.24	$0.30	+$0.06	$0.18	N/A	$796.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMRX Amneal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
LQDA Liquidia	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMRX Amneal Pharmaceuticals	77.65	2.20	1.44
AXSM Axsome Therapeutics	1.52	1.43	1.34
LNTH Lantheus	0.43	3.06	2.89
LQDA Liquidia	0.63	2.31	2.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMRX Amneal Pharmaceuticals	31.82%
AXSM Axsome Therapeutics	81.49%
LNTH Lantheus	99.06%
LQDA Liquidia	64.54%

Insider Ownership

Company	Insider Ownership
AMRX Amneal Pharmaceuticals	17.30%
AXSM Axsome Therapeutics	20.60%
LNTH Lantheus	1.70%
LQDA Liquidia	25.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMRX Amneal Pharmaceuticals	8,500	319.35 million	264.11 million	Optionable
AXSM Axsome Therapeutics	925	52.38 million	41.59 million	Optionable
LNTH Lantheus	1,193	65.27 million	64.16 million	Optionable
LQDA Liquidia	216	89.51 million	66.60 million	Optionable

LQDA, AXSM, LNTH, and AMRX Headlines

Recent News About These Companies

Liquidia Corporation and United Therapeutics Reach Global Settlement Resolving All Pending Litigation

1 hour ago | quiverquant.comQ

Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH

1 hour ago | globenewswire.com

Liquidia Negatively Rated Stock Pick of the Week at Smart Insider Following Chairman's Share Sale

October 13 at 1:53 PM | finance.yahoo.com

Liquidia Corporation (LQDA) Securities Investigation Notice - Levi & Korsinsky

October 12 at 2:55 PM | prnewswire.com

Liquidia (NASDAQ:LQDA) Shares Gap Up - What's Next?

October 12 at 11:01 AM | americanbankingnews.com

Liquidia (NASDAQ:LQDA) Shares Gap Up - Here's Why

October 12 at 10:59 AM | marketbeat.com

Liquidia (NASDAQ:LQDA) Shares Gap Down - Time to Sell?

October 9, 2026 | marketbeat.com

Liquidia (NASDAQ:LQDA) Stock: Insider Stephen Bloch Sells 235,477 Shares

October 9, 2026 | americanbankingnews.com

Liquidia (NASDAQ:LQDA) Shares Up 5.5% - Here's What Happened

October 8, 2026 | marketbeat.com

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Liquidia Corporation (LQDA)

October 8, 2026 | globenewswire.com

Liquidia stock faces patent risk after two claims are found valid

October 8, 2026 | ad-hoc-news.deA

Liquidia (NASDAQ:LQDA) Director Sells $6,388,491.01 in Stock

October 8, 2026 | insidertrades.com

LQDA Investors with $100,000 in Losses Have Opportunity to Join Liquidia Corporation Fraud Investigation with SBS Law

October 7, 2026 | businesswire.com

Liquidia (NASDAQ:LQDA) Director Stephen Bloch Sells 235,477 Shares of Stock

October 7, 2026 | marketbeat.com

LIQUIDIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Liquidia Corporation on Behalf of Liquidia Stockholders and Encourages Investors to Contact the Firm

October 7, 2026 | globenewswire.com

Liquidia (LQDA) Could Be 74% Undervalued As Court Ruling Clouds YUTREPIA Access

October 7, 2026 | finance.yahoo.com

Analysts Are Bullish on Top Healthcare Stocks: Liquidia Technologies (LQDA), Kodiak Sciences (KOD)

October 6, 2026 | theglobeandmail.com

LQDA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Liquidia Corporation

October 6, 2026 | prnewswire.com

HC Wainwright Estimates Liquidia's Q3 Earnings (NASDAQ:LQDA)

October 6, 2026 | americanbankingnews.com

HC Wainwright Has Negative Forecast for Liquidia Q3 Earnings

October 6, 2026 | marketbeat.com

Liquidia Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Liquidia (LQDA)

October 5, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LQDA, AXSM, LNTH, and AMRX Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

$19.57 -0.46 (-2.30%)

Closing price 04:00 PM Eastern

Extended Trading

$19.73 +0.16 (+0.80%)

As of 07:30 PM Eastern

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Axsome Therapeutics NASDAQ:AXSM

$156.32 -9.68 (-5.83%)

Closing price 04:00 PM Eastern

Extended Trading

$157.64 +1.32 (+0.84%)

As of 07:38 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Lantheus NASDAQ:LNTH

$100.02 -0.09 (-0.09%)

Closing price 04:00 PM Eastern

Extended Trading

$100.04 +0.02 (+0.01%)

As of 07:31 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Liquidia NASDAQ:LQDA

$26.81 -0.86 (-3.11%)

Closing price 04:00 PM Eastern

Extended Trading

$38.54 +11.73 (+43.75%)

As of 07:40 PM Eastern

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LQDA, AXSM, LNTH, and AMRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LQDA, AXSM, LNTH, and AMRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LQDA, AXSM, LNTH, and AMRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LQDA, AXSM, LNTH, and AMRX Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

Axsome Therapeutics NASDAQ:AXSM

Lantheus NASDAQ:LNTH

Liquidia NASDAQ:LQDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LQDA, AXSM, LNTH, and AMRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LQDA, AXSM, LNTH, and AMRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LQDA, AXSM, LNTH, and AMRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LQDA, AXSM, LNTH, and AMRX Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

Axsome Therapeutics NASDAQ:AXSM

Lantheus NASDAQ:LNTH

Liquidia NASDAQ:LQDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools